低分子量肝素治疗急性前循环脑梗死疗效观察—附34例报告  

Therapeutic Efficacy of LMWH in Treatment of 34 Cases with Acute Anterior Circulatory Cere-bral Infarction

作　　者：叶妮[1] 张临洪[1] 

机构地区：[1]武汉市中心医院神经内科,武汉430014

出　　处：《临床急诊杂志》2002年第4期159-161,共3页Journal of Clinical Emergency

摘　　要：目的:研究低分子量肝素治疗急性前循环脑梗死的有效性和安全性。方法:选择我院2000年6月～2001年6月收治的在发病48小时内就诊的急性前循环脑梗死患者,随机分为观察组(34例)和对照组(34例)。观察组患者使用低分子量肝素皮下注射(4 100u,每12小时1次,共10天)。于治疗前及治疗后10、21、28天评定临床神经功能缺损程度及疗效。结果:观察组治疗前后临床神经功能缺损评分比较具有极显著差异(P<0.01),与对照组比较有显著差异(P<0.05);第28天两组总有效率分别为76.5%和55.9%,两组比较有极显著差异(P<0.001)。结论:低分子量肝素治疗急性前循环脑梗死是安全有效的。Purpose;To study the efficiency and safety of low-molecular-weight heparin( LMWH) in treatment of acute anterior circulatory cerebral infarction(ACI). Methods; 68 patients suffering acute ACI within 48 hours of the onset of symptems were randomly allocated to a test group and a control group (34 patients for each group). LMWH was employed to the test group through subcutaneous injection(4 l00u for every 12 hours) for 10 days. Neurological deficits score of stroke (NDSS) and therapeutic efficiency were clinically evaluated on a pre-treatment date and the 10th-、21st-、28th-day after treatment. Results: The result of the test group revealed highly obvious differences in NDSS between pre-treatment and post-treatment ( P <0. 01) ,and compared with the control group, the score of post-treatment was highly re-duced ( P <0. 05). Total difference was apparent ( P <0. 01). Conclusion: This study showed that LM-WH is effective and safe in treatment of acute anterior-circulatory cerebral infarction.

关 键 词：低分子量肝素 急性前循环脑梗死 治疗 

分 类 号：R743.330.5[医药卫生—神经病学与精神病学]